CAR-T Cell Therapies Platform

Chimeric antigen receptor (CAR)-T cell therapy represents a major advancement in personalized cancer treatment. This therapy has shown remarkable results with hematological malignancies (including anti-CD19 CAR-T therapy against B cell malignancies).  To help accelerate research in this field, we provide a comprehensive, end-to-end platform of in vitro services and in vivo animal models for supporting project teams focused on the discovery of CAR-T cell therapies.

T cells, cancer cells
CAR-T, chimeric antigen receptor, malignancies

In vitro Assays and Services

  • CAR design and construction (sequence optimization, lentiviral vector selection)
  • Packaging of viral particles (titration, viral copy number)
  • Optimization of transfection efficiency of CAR-T cells with lentiviral transduction enhancers
  • Functional evaluation, including cytotoxicity testing (co-culturing CAR-T cells and tumor cells) and measurements of cytokine release
  • Optimization of culture media and conditions for CAR-T cell proliferation
  • Analysis of CAR expression via flow cytometry
  • Expansion of CAR-T cells and phenotype characterization (differentiation of T cells)
  • Biomarker services (multiplexed tissue staining)
  • Safety QC assessment (endotoxin, mycoplasma)
chimeric antigen receptor, CAR-T, CD19, lentiviral vector, transduction, DNA quantification

In vivo Animal Models

  • Extensive portfolio of PDX models, with biomarkers
  • Panel of more than 280 CDX models, covering 29 tumor types
  • Syngeneic models
  • Orthotopic and metastatic models
  • PBMC or HSC humanized models
chimeric antigen receptor, CAR-T, efficacy in vivo testing, PDX, CDX, syngeneic, PBMC, HSC models

In vivo Efficacy

In vivo anti-tumor
efficacy
• Endpoints: Tumor volume measurement for subcutaneous models; bioluminescence imaging for systemic models and orthotopic models; survival analysis
• Clinical Observation: Food consumption, body weight, behavior and morphology, necropsy at the endpoint
CAR-T viability and biodistribution• In vivo proliferation, survival, and long-term persistence of CAR-T cells
• Tumor or tissue distribution and infiltration of CAR T cells
• T cell phenotype analysis (Memory and effector T cells, Tregs)
Toxicity evaluation
(non-GLP)
• Cytokine release analysis
• Single dose toxicity
• Potential tumorigenicity of CAR-T cells
  • Tumor volume measurements (for subcutaneous models)
  • Bioluminescence imaging (for systemic and orthotopic models)
  • Survival analysis
  • Clinical observations (including necropsy at endpoint)
  • Infiltration of CAR-T cells in tumor and tissue
  • Proliferation, survival, and long-term persistence of CAR-T cells
  • T cell phenotype analysis (e.g., memory and effector T cells, Tregs)
  • Toxicity assessment (including single-dose toxicity and cytokine release)
chimeric antigen receptor, CAR-T, CD19, toxicity, tumor volume, proliferation, and tumorigenicity